美国东部时间12/6周六晚9点，北京时间12/7周日早10点，华人抗体协会的产业前沿线上讲座系列第22讲:微流控赋能抗体药物发现：高通量单B细胞筛选和SPR分子相互作用分析。我将担任本次讲座的主持，欢迎一起学习最新的微流控与SPR技术如何加速抗体筛选！

Dr. Ethan Yu博士是极瞳生命（Polariton Life）的创始人兼首席技术官。

Dr. Ethan Yu在光学生物传感器领域拥有逾二十年的研发经验，毕业于德国马克斯·普朗克高分子研究所，获博士学位（Summa Cum Laude），并于斯坦福大学完成博士后研究。 Dr. Ethan Yu曾成功主导开发全球首款无设备、定量CD4检测试剂盒，该创新成果荣获Frost & Sullivan技术创新大奖，并获得比尔及梅琳达·盖茨基金会的资助。2020年，他创立极瞳生命，致力于高端生命科学仪器的产业化。在其带领下，公司推出的S-CLASS SPR分子互作系统——一款高通量生物分子相互作用分析仪，正获得中美两国顶尖学术机构及制药企业的广泛认可与应用。

Dr. Ethan Yu is the founder and CTO of Polariton Life. With over 20 years of experience in optical biosensors, he holds a Ph.D. (Summa Cum Laude) from the Max-Planck-Institute for Polymer Research, followed by postdoctoral research at Stanford University. He previously led the development of the world's first equipment-free, quantitative CD4 test kit, earning Frost & Sullivan innovation award and grant funding from Gates Foundation. In 2020, he founded Polariton Life, aiming to commercialize high-end life science instruments. Under his leadership, Polariton Life has launched the S-CLASS SPR system, a high-throughput biomolecular interaction instrument, which is gaining wide adoption by leading academic and pharmaceutical institutions in China and US.

讲座题目：Democratizing SPR systems for high performance modern drug discovery workflow

概要：表面等离子体共振（SPR）作为一种金标准技术，在药物研发领域被广泛应用于生物分子相互作用的实时、无标记分析。该技术在整个治疗性药物开发流程中，对表征结合亲和力、动力学及特异性至关重要。然而，其在学术实验室、生物科技初创企业及核心设施中的广泛采用仍面临显著障碍。这些障碍包括商业系统的高昂资本支出、复杂仪器和软件带来的陡峭学习曲线，以及对实验室自动化造成限制的封闭生态系统。极瞳生命的SPR系统专为突破这些局限而设计。我们开发的平台在保证数据质量不受妥协的同时，成功打破了传统使用壁垒。我们的仪器以远低于市场主流系统的成本，实现了顶尖水平的性能表现，提供高灵敏度和可靠的动力学分析。此外，我们通过流线型软件优化用户体验，显著降低了操作所需的培训周期和专业门槛。通过倡导仪器与软件的开放灵活架构，我们为研究人员提供了更自主的选择和控制权。极瞳生命正在让高精度的SPR技术变得更易普及、更经济实用、更便捷易用，从而加速该技术在现代药物研发工作流程中的集成应用。

Webinar Title：Democratizing SPR systems for high performance modern drug discovery workflow

Abstract: Surface Plasmon Resonance (SPR) is a gold-standard technique extensively used in drug discovery for the real-time, label-free analysis of biomolecular interactions. It is critical for characterizing binding affinity, kinetics, and specificity throughout the therapeutic development pipeline. However, its wider adoption in academic labs, biotech startups, and core facilities is often hindered by significant barriers. These include the high capital expenditure of commercial systems, steep learning curves associated with complex instrumentation and software, and vendor-locked ecosystems that is restrictive to lab automation. Polariton Life's SPR system is engineered specifically to address these limitations. We have developed a platform that breaks down the traditional barriers to access without compromising on data quality. Our instrument delivers best-in-class performance, offering high sensitivity and robust kinetic analysis, but does so at a fraction of the cost of incumbent systems. Furthermore, we prioritize intuitive user experience with streamlined software, significantly reducing the training and expertise required. By championing open, flexible architecture for our instruments and software, we empower researchers with greater choice and control. Polariton Life is thus making high-fidelity SPR technology more accessible, affordable, and user-friendly, accelerating its integration into the modern drug discovery workflow.

本期主讲人: Jennifer Sun

Dr. Jennifer Sun是一位拥有二十余年经验的创新领袖、企业家及科学家，专注于微流控技术、生物材料、器官芯片及先进制造等前沿领域。现任达普生物（DPBIO）全球应用科学家总监，负责推动液滴微流控平台在抗体发现与单细胞分析中的技术应用与产业化落地。Dr. Sun拥有哈佛大学与复旦大学联合培养博士学位，曾在Allegro 3D与BMF Precision担任关键领导职务，主导生物医疗技术的研发、产品开发及商业化。她在Allegro 3D的杰出贡献为公司成功并入Cellink 并被生物融合领域的领军企业BICO集团收购奠定了重要基础。作为科研经验与成果兼备的科学家，Dr. Sun融合深厚的学术功底与敏锐的创新洞察，持续推动前沿技术向可落地、有影响力的生物医药应用转化，助力生命科学创新发展。

Dr. Jennifer Sun is an innovation leader, entrepreneur, and scientist with over 20 years of experience spanning microfluidics, biomaterials, organ-on-a-chip, and advanced manufacturing. She is currently Global Director of Field Application Scientists at DPBIO, where she leads the implementation of droplet microfluidics platforms for antibody discovery and single-cell analysis.

Dr. Sun holds a joint Ph.D. from Harvard University and Fudan University. She previously held leadership roles at Allegro 3D and BMF Precision, driving R&D, product development, and commercialization of novel biomedical technologies. Her contributions at Allegro 3D played a key role in positioning the company for its merger with Cellink and acquisition by BICO, a global leader in bioconvergence. An accomplished inventor and published researcher, Dr. Sun combines deep scientific expertise with entrepreneurial insight to translate innovations into impactful, real-world applications.

讲座题目: Empowering Single B Cell Monoclonal Antibody Discovery: High-Throughput Plasma B Cell Screening with DPBIO’s CytoSpark®

概要：新一代治疗性药物的研发正随着单B细胞抗体筛选和功能酶筛选技术的进步而不断发展。达普生物（DPBIO）凭借自主研发的 CytoSpark® 液滴微流控高通量筛选平台，正在引领这一变革，使单细胞水平的快速、功能性筛选成为可能。CytoSpark® 平台以浆B细胞为核心，支持多物种（包括兔、小鼠、羊驼及人源）的抗体直接筛选。相比传统方法，平台在筛选速度、多样性和功能验证方面具有显著优势。不仅能高效发现针对膜蛋白、GPCR等难靶点的抗体，还能识别具有特定功能的抗体类型，如激动型、阻断型和中和型抗体，突破了仅以结合能力为导向的筛选局限。除了抗体发现，CytoSpark® 还可广泛应用于酶定向进化与功能筛选，为科研人员提供灵活高效的研究工具，加速新型生物制品、细胞系及合成生物学应用的开发。凭借单细胞级的精准分析、高通量的筛选能力以及对功能的直接关联，达普生物正助力生物制药创新模式的重塑，推动生命科学研究迈向新的阶段。

Webinar Title：Empowering Single B Cell Monoclonal Antibody Discovery: High-Throughput Plasma B Cell Screening with DPBIO’s CytoSpark®

Abstract: The next generation of therapeutic discovery is being shaped by advances in single B cell monoclonal antibody screening and functional enzyme discovery. At DPBIO, we are leading this transformation with CytoSpark®, a cutting-edge high-throughput droplet microfluidics platform that enables rapid, functional screening at the single-cell level. Built around plasma B cell-based discovery, CytoSpark® offers direct screening capabilities for a wide range of species, -including rabbit, mouse, alpaca, and human- delivering faster timelines, higher diversity, and stronger functional outcomes compared to conventional approaches. The platform supports not only the discovery of antibodies against difficult targets such as membrane proteins and GPCRs, but also the identification of functional antibodies such as agonists, blockers, and neutralizers that go beyond simple binding. Beyond antibody discovery, CytoSpark® extends its power to enzyme evolution and functional screening, offering researchers a versatile tool to accelerate the development of novel biologics, cell lines, and synthetic biology applications. Through single-cell precision, high-throughput speed, and functional relevance, DPBIO is helping reshape the future of biopharmaceutical innovation.

请点击二维码注册讲座

本期赞助商介绍

友情提醒

• 我可以最后一分钟注册讲座吗? 请尽量至少提前一天注册

• 我注册成功了吗？注册成功后会收到确认邮件，邮件含有当日连入webinar的链接，点击链接即可顺利进入webinar

• 我没有收到邮件？检查一下您的自动过滤邮箱

• 我用什么软件参加讲座？讲座使用Zoom平台，PC，苹果和安卓系统都可以下载 

• 第一次参加，我的电脑和手机操作系统适合吗？邮件中提供了系统测试链接， 一试便知

• 可以观看本期和往期视频回放吗？华人抗体协会注册会员可以在讲座结束后登录华人抗体协会网主页观看本期和往期视频回放

• 还有其他问题和建议？请随时在微信文章末尾留言或在会员微信群求助

关于华人抗体协会的Industrial Frontier讲座系列

Webinar系列自2017年年中启动以来，主要围绕抗体药从研发到上市的整个产业链进行设置。本期的Industrial Frontier Webinar Series是我们推出的最新的Webinar讲座系列，目的是为华人抗体协会企业会员对该企业最新的技术平台提供一个分享的平台。

Webinar目前采用Zoom在线系统：https://www.zoom.com/ 每个webinar总时长为1小时-1个半小时，采用presentation + 15分钟 Q & A的形式进行，以增进观众与报告人的互动和交流。讲座的幻灯片以及讲座时使用的语言将根据报告人的偏好采用中文或者英文。

Industrial Frontier Webinar Series系列将对公众免费开放。请点击二维码注册讲座，或者请登录https://chineseantibody.net/cas-live-webinar-series-industry-frontier/或点击文末阅读原文（Read more)免费注册参加这个webinar。注册后会收到确认和提醒邮件, 可直接点击邮件中的webinar链接进入讲座。每次webinar过程中， 协会鼓励和欢迎注册听众进入webinar微信讨论群。听众可以通过讲座系统平台或者微信群平台向主讲人提出或讨论问题。请在线的会员充分利用实时webinar的机会与主讲人积极的问答互动。

赞助与合作机会 

华人抗体协会欢迎抗体领域的企业成为华人抗体协会的企业会员，有意参与的公司请联系：sponsorship@chineseantibody.org。协会将为企业会员提供宣传展示自己公司的机会。

《Antibody Therapeutics》是华人抗体协会（ChAbS）的旗下期刊，由牛津大学出版社（Oxford University Press）出版。作为一本同行评审的开放获取期刊，Antibody Therapeutics 为全球科学界提供了一个平台，用于发表治疗性抗体在发现、研究、开发及相关方法学方面的最新进展与挑战。该期刊已被ESCI（影响因子=4.5）、Scopus（CiteScore=8.4）及PubMed Central等主要文献数据库收录。

期刊官网：https://academic.oup.com/abt （点击文末阅读原文直达官网）

期刊Linkedin: https://www.linkedin.com/company/antibody-therapeutics

华人抗体协会是一个非营利、非政府的公益性组织，是第一个也是目前唯一一个全球性华人抗体专业组织。协会侧重关注治疗性抗体，并致力于创建一个全球性平台，以促进在治疗性抗体研发，生产以及商业化等领域的合作与交流。关于协会更多介绍请参阅：华人抗体协会简介与发展简史

华人抗体协会与牛津大学出版社合作，出版同行评审英文专业期刊: Antibody Therapeutics。

华人抗体协会网站：

www.chabs.org

Follow us at LinkedIn: 

www.linkedin.com/company/chabs-华人抗体协会

​